The FDA granted another indication for Sensus Healthcare‘s topical skin cancer device, for treating keloid scars.
The Danbury, Conn.-based medical device company said its SRT-100 "superficial radiotherapy" product has already won 510(k) clearance from the federal watchdog for treating some skin cancers.